What We're Reading: Page 104
Industry reads hand-picked by our editors
Apr 24, 2023
-
The Wall Street Journal
J&J Consumer-Health IPO Process to Kick Off Key Test for Moribund New-Issue Market
-
Reuters
‘It totally backfired’: The pitfalls of Alzheimer’s genetic testing
-
KFF Health News
Pain, Hope, and Science Collide as Athletes Turn to Magic Mushrooms
-
Healthcare Dive
‘Hurtling into the future’: The potential and thorny ethics of generative AI in healthcare
Apr 21, 2023
-
Reuters
Lilly expects US Medicare to reverse course, fully cover Alzheimer’s drugs
-
Financial Times
Activist investor ramps up pressure on incoming Bayer boss
-
Axios
Drug pricing rules set up potential challenge from pharmaceutical industry
-
Bloomberg
Virus Hunters Search for Diseases Supercharged by Climate Change
Apr 20, 2023
Apr 19, 2023
-
Bloomberg
Big Drugmakers Like Merck Are Forced to Pay Up in M&A for R&D Neglect
-
The Wall Street Journal
Unexpected Ozempic Side Effect? Weird Dreams
-
C&EN
Generative AI is dreaming up new proteins
Apr 18, 2023
-
Fierce Pharma
Struggling Gamida wins long-awaited FDA approval for Omisirge
-
FirstWord Pharma
Lilly pours another $1.6 billion to buoy drug manufacturing in home base
-
Bloomberg
Danaher Is Said to Shelve Takeover Pursuit of Catalent
-
Regulatory Focus
ORA head says attrition is outpacing hiring, decries flat funding for inspections
Apr 17, 2023
-
The Wall Street Journal
Demand for Obesity Drugs Has Insurers Paying Close Attention
-
Reuters
GSK’s antibiotic drug to treat uncomplicated UTIs meets main goals
-
Financial Times
Gates Foundation makes unusual investment in experimental cancer trial
-
The New York Times
CoolSculpting Promised to Zap Fat. For Some, It Brought Disfigurement.
Apr 14, 2023
-
LifeSciVC
Biotech Funding: Times Are Tough, Maybe For The Better
-
Science
Judicial interference with mifepristone
-
Bloomberg
Biden’s Medicare Chief Is Crafting How Program Will Negotiate Drug Prices
-
Generative AI is dreaming up new proteins
Previous
